On Mar. 9, 2020, Humanigen announced that it was actively exploring clinical stage strategies and partnerships to evaluate whether lenzilumab, the company’s proprietary Humaneered anti-human-GM-CSF monoclonal antibody, may reduce or prevent cytokine storm resulting from COVID-19 (or coronavirus) infection.